<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Mol Microbiol. 2008 April ; 68(1): 37&#226;&#8364;&#8220;50. doi:10.1111/j.1365-2958.2008.06131.x. <br />  <br />  <br />  <br />                            Characterization Trypanosoma brucei dihydroorotate <br />                            dehydrogenase possible drug target; structural, kinetic                            RNAi studies <br />  <br />                            Tracy L Arakaki*,1,2, Frederick S Buckner*,2,3, J Robert Gillespie3, Nicholas Malmquist4, <br />                            Margaret Phillips4, Oleksandr Kalyuzhniy1,2, Joseph R Luft2,5, George T DeTitta2,5, <br />                            Christophe L M J Verlinde1,2, Wesley C Van Voorhis2,3, Wim G J Hol1,2, Ethan                            Merritt1,2,&#226;&#8364;&#160; <br />                            1Department Biochemistry, University Washington, Seattle, WA 98195 USA <br />  <br />                            2Structural   Genomics Pathogenic Protozoa (SGPP), www.sgpp.org <br />                            3Department      Medicine, University Washington, Seattle, WA 98195 USA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            4Department Pharmacology, University Texas Southwestern Medical Center, Dallas, TX 75390 <br />  <br />                            USA <br />                            5Hauptman      Woodward Institute, Buffalo, NY USA <br />  <br />                            Abstract <br />                                  <span id='am-47' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-48' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span><span id='am-51' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-52' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span><span id='am-53' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span><span id='am-54' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span>Nucleotide</span> biosynthesis pathways reported essential protozoan pathogens. <br />                                   evaluated essentiality enzyme pyrimidine biosyn-thetic pathway, <br />                                  dihydroorotate dehydrogenase (DHODH) eukaryotic parasite Trypanosoma brucei                                  gene knockdown studies. RNAi knockdown DHODH expression bloodstream-form T. brucei <br />                                  did inhibit growth normal medium, profoundly retarded growth pyrimidine-depleted <br />                                  media presence known pyrimidine uptake antagonist 5-fluoruracil (5-FU).                                  results significant implications development therapeutics combat T. brucei <br />                                  infection. Specifically, combination therapy including T. brucei-specific DHODH inhibitor plus <br />                                  5-FU prove effective therapeutic strategy. trypanosomal enzyme <br />                                  inhibited known inhibitors bacterial Class 1A DHODH, distinction sensitivity                                  DHODH human higher eukaryotes. selectivity supported crystal <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                  structure T. brucei enzyme, reported resolution 1.95 &#195;&#8230;. Additional research, <br />                                  guided crystal structure described  needed identify potent inhibitors T. brucei <br />                                  DHODH. <br />  <br />  <br />                            Keywords <br />                                  flavoprotein; pyrimidine biosynthesis; gene knockdown; kinetoplastid; RNAi <br />  <br />  <br />                            INTRODUCTION <br />                                             Pyrimidine biosynthesis vital biological process, achieved novo synthesis                                             pyrimidine salvage pathways.  parasitic protozoa deficient pyrimidine <br />  <br />                            &#226;&#8364;&#160; <br />                             Correspondence  Ethan Merritt, Dept Biochemistry, Box 357742, University Washington, Seattle, WA 98195. Phone: (206) <br />                            543-1421; Fax: (206) 685-7002; merritt@u.washington.edu. <br />                            *Contributed equally <br />                             Arakaki et al.                                                                                              Page 2 <br />  <br />  <br />                                             salvage (Chaudhary Roos, 2005) enzymes pyrimidine synthesis pathway <br />                                             considered potential drug targets. fourth enzyme pathway                                             dihydroorotate dehydrogenase (DHODH), oxidizes dihydroorotate orotate, NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             aromatic intermediate pathway, consequent transfer electrons protein <br />                                             cofactor FMN (Figure 1). Recent experiments validate DHODH drug target                                             Trypanosoma cruzi showed insect-stage epimastigotes dependent novo synthesis <br />                                             pyrimidines (Annoura et al., 2005). Specifically, gene interruption gene loci <br />                                             encoding cytosolic DHODH T. cruzi led cell non-viability; addition pyrimidine <br />                                             nucleosides medium did rescue DHODH knockdown cells.                                             undertook extensive investigation essentiality closely homologous gene <br />                                             T. brucei, causative agent African Sleeping Sickness. <br />  <br />                                             DHODHs categorized classes, Class 1 Class 2, based sequence, <br />                                             localization cell, electron <span id='am-99' about='obo:IMR_0200224' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-100' property="oboInOwl:id" content="IMR:0200224" datatype="xsd:string"></span><span id='am-101' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-102' property="rdfs:label" content="Acceptor" datatype="xsd:string"></span><span id='am-103' property="oboInOwl:hasDbXref" content="KEGG:C00028" datatype="xsd:string"></span>acceptor</span> used reoxidize FMN second half- <br />                                             reaction (Nielsen, Andersen Jensen, 1996; Nielsen, Rowland, Larsen Jensen, 1996). <br />                                             classes belong Pfam sequence family PF01180. Class 1 DHODHs primarily <br />                                             bacterial. cytosolic divided 1A (E.C. 1.3.3.1) 1B (E.C. 1.3.1.14) <br />                                             depending electron acceptor oligomeric state. Class 2 DHODHs, including                                             human plasmodial enzymes, monomeric contain mitochondrial targeting sequences <br />                                             located N-terminal domain (Rowland et al., 2000). Furthermore,                                             inner membrane mitochondria (Knecht et al., 1996) associated cytoplasmic <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             membranes case E. coli (Karibian, 1978). Specific inhibitors known                                             classes (Palfey et al., 2001; Baldwin et al., 2005). <br />  <br />                                             present genomic, biochemical, structural evidence TbDHODH Class 1A <br />                                             DHODH, particular inhibited Class 1A specific inhibitors. structural <br />                                             analysis based 1.95&#195;&#8230; resolution crystal structure T. brucei enzyme crystallized <br />                                             reaction product orotate. present kinetic, inhibition, biophysical, RNAi <br />                                             knockdown data T. brucei DHODH, previously characterized. <br />                                             Furthermore RNAi knockdown T. brucei DHODH synergistic                                             effects 5-fluorouracil (5-FU), inhibitor pyrimidine uptake T. brucei  Koning                                             Jarvis, 1998). finding provides rationale develop DHODH inhibitors                                             used combination 5-FU inhibitor pyrmidine uptake yield potent <br />                                             regimen. encouraged structure inhibition studies offer insight                                             stereochemical functional details active site trypanosomal enzyme,                                             facilitate development lead compounds anti-trypanosomal drug discovery.                                             results essentiality enzyme divergent reported closely <br />                                             related T. cruzi parasite, underscore importance validating anti-protozoan drug <br />                                             targets separately target organism (Wang,1997). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               RESULTS <br />                                             DHODH gene T. brucei genome (GeneDB Tb927.5.3830).                                             gene initially identified structural genomics target (TargetDB Tbru015978)                                             Structural Genomics Pathogenic Protozoa consortium (SGPP). time work                                             initiated trypanosomal DHODH structures available, preliminary <br />                                             characterization Leishmania major DHODH presented (Feliciano et al., 2006)                                             preliminary crystallization T. cruzi enzyme reported (Inaoka et al., 2005).                                             undertook novo crystallographic structure determination T. brucei DHODH,                                             undertook biochemical characterization enzyme confirm assignment                                             trypanosomal enzymes Class 1A. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                             Page 3 <br />  <br />  <br />                               Structural analysis <br />                                             crystal structure TbDHODH determined 1.95&#195;&#8230; resolution single crystal <br />                                             space group C2221. Consistent previously determined structures sequence <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             family, overall fold TbDHODH monomer &#206;&#177;&#206;&#178; barrel prosthetic FMN <br />                                             group located near C-terminus (Figure 2a). <br />  <br />                                             asymmetric unit crystal structure contains monomers arranged                                             distinct dimers. monomers dimer related fold symmetry dimer <br />                                             overlays L. lactis 1A dimer. area contact dimer interface 2300 <br />                                             &#195;&#8230;2 analyzed PDBsum (Laskowski et al., 2005). interface includes 19 inter-monomer <br />                                             hydrogen bonds salt bridge Glu208 monomer Lys297 monomer B. <br />                                             salt bridge observed L. lactis structure. Lys297 strictly conserved                                             Class 1A DHODHs; residue 208 conserved glutamate aspartate (Fig. S2).  <br />                                             salt bridge characteristic feature dimer interface Class 1A DHODHs. <br />  <br />                                             oligomeric state protein examined analytical ultracentrifugation. TbD- <br />                                             HODH observed protein absorption 280 nm FMN absorption 454 nm. <br />                                             centrifugation experiments, single ideal species model consistently yielded                                             average mass indicative dimeric enzyme, monomer/dimer model reliably produced <br />                                             sub-micromolar dissociation constants dimerization (Fig. S1). biophysical result <br />                                             supports crystallographic observation TbDHODH homodimer. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             TbDHODH structure contains cis-peptides, Glu56-Pro57 Cys193-Val194.                                             cis-peptides observed structures L. lactis 1A, L. lactis 1B, human Class <br />                                             2 homologs. residues following cis-<span id='am-1' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-2' property="rdfs:label" content="peptide" datatype="xsd:string"></span><span id='am-3' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span><span id='am-4' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>peptide</span>, Arg58 Tyr59, close <br />                                             proximity active site highly conserved Class 1A DHODH sequences.                                             exceptional stereochemistry observed refined TbDHODH model. <br />  <br />                               FMN binding site <br />                                             FMN prosthetic group located near dimer interface pocket formed predominantly <br />                                             strands &#206;&#178;4, &#206;&#178;6&#226;&#8364;&#8220;7, &#206;&#178;11, &#206;&#178;17. FMN forms hydrogen bonds residues Ala20, Ser45, <br />                                             Lys44, Cys249, Val194, Lys165 (Fig. S3); hydrophobic interactions residues <br />                                             Ala19, Gly21, Met70, Tyr59, Asn68, orotate. isoalloxazine ring FMN                                             aromatic ring orotate parallel DHODH-orotate structures.                                             dimethylbenzene moiety isoalloxazine ring lacks close contacts residue <br />                                             solvent accessible. differs FMN binding site human structure (25% <br />                                             sequence identity), Class 2-specific N-terminal domain blocks access active <br />                                             site. similar hydrogen bonding interactions FMN TbDHODH NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             human structures residues conserved structures Lys44 <br />                                             Cys249. sulfhydryl Cys249 forms hydrogen bond O3 ribityl group                                             FMN. equivalent interaction absent human structure,                                             hydrogen bond O3. sequence-based structure alignment, Lys44 <span id='am-55' about='obo:IMR_0100118' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001695 obo:IMR_0000001 obo:IMR_0100116'><span id='am-56' property="oboInOwl:hasAlternativeId" content="IMR:0200057" datatype="xsd:string"></span><span id='am-57' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-58' property="rdfs:label" content="glycine" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasExactSynonym" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-60' property="rdfs:label" content="Gly" datatype="xsd:string"></span><span id='am-61' property="oboInOwl:hasExactSynonym" content="Glycine" datatype="xsd:string"></span><span id='am-62' property="oboInOwl:hasDbXref" content="KEGG:C00037" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:id" content="IMR:0100118" datatype="xsd:string"></span><span id='am-64' property="rdfs:label" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-65' property="rdfs:label" content="Glycine" datatype="xsd:string"></span><span id='am-66' property="oboInOwl:hasExactSynonym" content="Gly" datatype="xsd:string"></span>glycine</span> human <br />                                             structure nearby lysine (hLys100), forms hydrogen bonds O4                                             isoalloxazine ring plays role binding FMN. <br />  <br />                                             residues TbDHODH form hydrophobic interactions FMN,                                             different human protein. differences potential use designing                                             inhibitor targeting FMN binding site differential specificity human                                             trypanosomal enzymes. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                               Page 4 <br />  <br />  <br />                               Orotate binding site conserved motifs Class 1A DHODH <br />                                             Class 1 Class 2 DHODHs differ active site base responsible abstraction                                             proton C5 orotate. Class 1A DHODHs base cysteine; Class 2 enzymes, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             including human DHODH, serine (N&#195;&#184;rager et al., 2003). TbDHODH, S&#206;&#179; active <br />                                             site base Cys131 3.65 &#195;&#8230; away C5 orotate. distance slightly longer                                             3.3 &#195;&#8230; observed L. lactis DHODH:orotate structure. present crystal structure pH <br />                                             4 cysteine sulfur likely protonated. Residues 126&#226;&#8364;&#8220;143, spanning region                                             active site Cys, strongly conserved Class 1A DHODHs (Fig. S2). <br />                                             residues described pyrimidine binding motif: EZNLSCPNZPUKZQXXYD, <br />                                             U polar uncharged residue, X non-specific residue hydrophobic <br />                                             residue. <br />  <br />                                             structure-based sequence alignment T. brucei, L. lactis 1B, human DHODHs, <br />                                             representing Classes 1A, 1B 2, respectively, shows Class 1 sequences                                             insertion 15 residues (residues 202&#226;&#8364;&#8220;216) relative human Class 2 sequence (Figure 3). <br />                                             residues form strand-loop-strand-loop (&#206;&#178;14-loop-&#206;&#178;15-loop) structural unit. Residues <br />                                             195&#226;&#8364;&#8220;203 preceding insertion conserved Class 1A DHODHs form                                             NSXGNGLXI motif (1A motif 1) close proximity active site. Asn195                                             conserved Asn residues interact orotate. <br />  <br />                                             orotate binding site flanked loop consisting residues 132&#226;&#8364;&#8220;138 (Fig. S4). NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             loop highly conserved Class 1A DHODHs (Fig. S2). crystal structures human <br />                                             DHODH corresponding loop poorly ordered, loop flexibility hypothesized allow <br />                                             active site open dihydroorotate enter orotate exit (Liu et al., 2000). <br />                                             contrast human structure, loop present TbDHODH structure relatively <br />                                             closed conformation defined electron density.  orotate FMN <br />                                             binding sites accessible TbDHODH human structure absence <br />                                             N-terminal domain characteristic Class 2 DHODH (Figure 2). difference                                             accessibility contribute differential sensitivity Class 1A Class 2 enzymes <br />                                             orotate analogues hydroxybenzoate. <br />  <br />                               RNA interference studies T. brucei DHODH <br />                                             Gene expression knockdown T. brucei DHODH achieved expressing                                             stem-loop RNA target gene bloodstream form T. brucei. Messenger RNA levels                                             decreased 95% 72 hours following induction RNA interference construct                                             addition tetracycline (Figure 4a). Knockdown T. brucei DHODH protein appeared                                             similarly substantial observed Western blots. monitored seven days,                                             protein levels detected &lt;5% levels observed RNAi induction (Figure 4b). NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             T. brucei cells grown standard medium (HMI-9), growth rates cells RNAi <br />                                             turned (TCN+) turned (TCN&#226;&#710;&#8217;) comparable (Figure 5a). growth rates <br />                                             cultures virtually control cells (&#226;&#8364;&#8482;single-marker&#226;&#8364;&#8482;) containing                                             T7 RNA polymerase Tet repressor genes maintained neomycin marker.                                             surprising observation normal cell growth led investigate parasites surviving <br />                                             scavenging pyrimidines medium. Note HMI-9 medium includes 16 &#194;&#181;M <br />                                             <span id='am-104' about='obo:IMR_0200384' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-105' property="oboInOwl:hasDbXref" content="KEGG:C00214" datatype="xsd:string"></span><span id='am-106' property="rdfs:label" content="Thymidine" datatype="xsd:string"></span><span id='am-107' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-108' property="oboInOwl:id" content="IMR:0200384" datatype="xsd:string"></span>thymidine</span>. additional thymidine omitted medium, saw                                             change growth phenotype induction RNA interference DHODH (data <br />                                             shown). standard medium 10% fetal bovine serum, repeated <br />                                             experiment using commercially available dialyzed serum, depleted small <br />                                             molecules pyrimidines. conditions observed reduced growth                                             induction RNAi construct. day 4 growth rate significantly reduced                                             arrested day 6 (Figure 5b). cells expressing RNAi construct                                             pyrimidine-depleted medium took bloated, balloon-shaped morphology day 5.  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                                 Page 5 <br />  <br />  <br />                                             small degree growth suppression TCN&#226;&#710;&#8217; cells compared single-marker <br />                                             controls, leaky expression RNAi construct. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             proceeded test RNAi knockdown DHODH impair growth <br />                                             standard medium inhibitor pyrimidine uptake present. 5-fluorouracil (5- <br />                                             FU) tested shown potent inhibitor pyrimidine uptake T. <br />                                             brucei (Gudin et al., 2006). inhibitory concentration 5-FU causing 50% growth <br />                                             inhibition (IC50) shifted 16-fold lower parasites undergoing knockdown DHODH <br />                                             (IC50 = 0.64 &#194;&#181;M) compared parasites undergoing knockdown (IC50 = 10.4 &#194;&#181;M) using <br />                                             standard medium (Figure 6). follow finding, tested uptake 3H-5-FU                                             DNA T. brucei cells observed uptake 2-fold higher                                             DHODH-knockdown parasites controls (Figure 7). <br />  <br />                               Classification TbDHODH Class 1A inhibition hydroxybenzoates <br />                                             TbDHODH activity examined presence standard DHODH terminal <br />                                             electron acceptors (Figure 8) catalyze fumarate efficiently, typical                                             Family 1A enzymes (Andersen et al., 1994). enzyme catalyzes reduction menadione <br />                                             (<span id='am-6' about='obo:IMR_0001656' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-7' property="rdfs:label" content="vitamin" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:id" content="IMR:0001656" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasDbXref" content="CHEBI:27305" datatype="xsd:string"></span>vitamin</span> K3) ~20% rate fumarate catalysis, does appear perform electron <br />                                             transfer menaquinone (vitamin K2), <span id='am-16' about='obo:IMR_0200483' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-17' property="oboInOwl:hasDbXref" content="KEGG:C00399" datatype="xsd:string"></span><span id='am-18' property="rdfs:label" content="Ubiquinone" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:id" content="IMR:0200483" datatype="xsd:string"></span>ubiquinone</span> analogues Q0, Q1, Q2, QD,                                             NAD+, characteristics Family 1A DHODH enzyme (Nara et al., 2000;Nielsen, <br />                                             Andersen Jensen, 1996;Marcinkeviciene et al., 2000). Catalysis DHO fumarate <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             displays saturation kinetics Km values 14 &#194;&#181;M DHO 80 &#194;&#181;M fumarate                                             Vmax 8.5 s&#226;&#710;&#8217;1 (Figure 9). pH dependence enzyme activity assayed (Figure 9 inset) <br />                                             peak activity occur pH 7.8, indicative ionizable groups pKa <br />                                             values 6.3 9.2 involved substrate binding catalysis. Analysis TbDHODH <br />                                             activity range DHO fumarate concentrations produces double-reciprocal plot <br />                                             parallel lines (Figure 10), indicative ping-pong mechanism consistent results <br />                                             Family 1A enzymes (Marcinkeviciene et al., 2000). <br />  <br />                                             Inhibition TbDHODH benzoate pyrimidine analogues initially performed 1 <br />                                             mM inhibitor (data shown). benzoate pyrimidine analogues tested, 3,4-                                             3,5-dihydroxybenzoate displayed inhibition 1 mM concentration. Subsequent analysis                                             TbD-HODH inhibition 3,4- 3,5-dihydroxybenzoate various inhibitor DHO <br />                                             concentrations (Figure 11) revealed competitive inhibition 3,4-dihydroxybenzoate                                             Ki ~58 &#194;&#181;M (determined IC50 plot, shown) weaker inhibition 3,5- <br />                                             dihydroxybenzoate, appeared non-competitive yielded Ki 200 &#194;&#181;M. values <br />                                             comparable reported Class 1A DHODHs (Feliciano et al., 2006; Takashima <br />                                             et al., 2002). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               DISCUSSION <br />                               Divergent pyrimidine requirement T. cruzi T. brucei <br />                                             Trypanosoma brucei genome contains enzymes required novo pyrimidine <br />                                             biosynthesis, indicating T. brucei capable providing pyrimidine pools <br />                                             (Berriman, 2004). fourth enzyme pathway, DHODH, considered potential <br />                                             drug target parasitic protozoa including P. falciparum T. cruzi (McRobert                                             McConkey, 2002; Annoura et al., 2005; Baldwin et al., 2005). particular, Class 1A <br />                                             DHODH T. cruzi shown gene disruption experiments necessary                                             growth epimastigotes (Annoura et al., 2005). performed functional, enzymatic,                                             structural studies protein related parasite T. brucei, causative agent African <br />                                             sleeping sickness, attempt confirm similar essentiality. <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                                Page 6 <br />  <br />  <br />                                             Functional studies using RNA interference block TbDHODH revealed bloodstream T. <br />                                             brucei able grow normally enzyme, apparently scavenging pyrimidines <br />                                             medium (Figure 5). ability scavenge pyrimidines entirely unexpected, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             shown T. brucei surface transporters capable importing <span id='am-94' about='obo:IMR_0200234' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-95' property="oboInOwl:id" content="IMR:0200234" datatype="xsd:string"></span><span id='am-96' property="rdfs:label" content="Uracil" datatype="xsd:string"></span><span id='am-97' property="oboInOwl:hasDbXref" content="KEGG:C00106" datatype="xsd:string"></span><span id='am-98' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>uracil</span>                                             cytosine  Koning Jarvis, 1998;Papageorgiou et al., 2005;Gudin et al., 2006). addition, <br />                                             T. brucei genome contains enzymes associated pyrimidine salvage, <br />                                             including <span id='am-21' about='obo:IMR_0200161' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-22' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-23' property="rdfs:label" content="Cytidine" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:hasDbXref" content="KEGG:C00475" datatype="xsd:string"></span><span id='am-25' property="oboInOwl:id" content="IMR:0200161" datatype="xsd:string"></span>cytidine</span> deam-inase (GeneDB Tb09.160.1680), uracil phosphoribosyltransferase <br />                                             (GeneDB Tb927.4.3320), thymidine kinase (GeneDB Tb10.70.7270). <br />  <br />                                              T. brucei, chemotherapeutic strategy deprive cells pyrimidine pools                                             appear require inhibition pyrimidine biosynthesis pyrimidine uptake/salvage. <br />                                             tested feasibility pronged attack repeating DHODH RNAi <br />                                             knockdown experiments presence 5-FU, compound previously demonstrated                                             inhibit pyrimidine uptake T. brucei (Gudin et al., 2006). 5-FU itself cytotoxic high <br />                                             concentrations inhibition thymidylate synthase incorporation DNA RNA <br />                                              Bono Twelves, 2001). observed cells undergoing dual treatment                                             affected DHODH knockdown, 16-fold sensitive 5-FU control <br />                                             cells (Figure 6). suggests cells tolerate inhibition pyrimidine <br />                                             synthesis inhibition pyrimidine uptake. <br />  <br />                                             5-FU inhibits pyrimidine uptake T. brucei, itself transported cells NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             relatively high efficiency (Gudin et al., 2006). possible cellular response suppression <br />                                             pyrimidine biosynthesis, case interference DHODH, regulate <br />                                             import pathway. follow experiment performed determine relative <br />                                             uptake radiolabelled 5-FU DNA T. brucei cells presence absence                                             DHODH suppression. experiment demonstrated &gt;2x higher 5-FU incorporation                                             DHODH knockdown cells controls (Figure 7). likely increased <br />                                             incorporation 5-FU DNA partly account enhanced sensitivity drug. <br />                                             speculate increased incorporation 5-FU DNA DHODH knockdown <br />                                             cells results following factors: 1) depletion intracellular <br />                                             pyrimidine pools favors incorporation 5-FU, 2) possible regulation enzymes <br />                                             convert 5-FU 5-fluorouracil monophosphate (FUMP), 5-fluorouracil diphosphate <br />                                             (FUDP), 5-fluorouracil <span id='am-42' about='obo:IMR_0200358' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-43' property="oboInOwl:hasDbXref" content="KEGG:C00536" datatype="xsd:string"></span><span id='am-44' property="oboInOwl:id" content="IMR:0200358" datatype="xsd:string"></span><span id='am-45' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-46' property="rdfs:label" content="Triphosphate" datatype="xsd:string"></span>triphosphate</span> (FUTP), 3) possible increased uptake 5-FU                                             regulated pyrimidine transporter activity cell surface. Future experiments                                             necessary better establish mechanisms responsible observations. <br />  <br />                                             Whichever mechanisms play, apparent synergy DHODH <br />                                             knockdown plus 5-FU treatment significant implications pursuing pyrimidine <br />                                             biosynthesis pathway drug target T. brucei. imagine combination treatment <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             including 5-FU new compound specifically inhibits T. brucei DHODH                                              possibly enzyme pyrimidine biosynthesis pathway). new DHODH inhibitor <br />                                             &#226;&#8364;&#339;chemosensitizer&#226;&#8364;? 5-FU dramatically enhance activity 5- <br />                                             FU treating T. brucei infection. 5-FU established clinical drug use <br />                                             1950&#226;&#8364;&#8482;s. known toxicities, certainly advantages existing <br />                                             human African trypanosomiasis drugs (e.g. melarso-prol, suramin, pentamidine, )                                             extremely toxic require parenteral administration. important develop partner <br />                                             drug inhibits T. brucei DHODH selectively. human DHODH Class 2 <br />                                             enzyme functionally structurally distinct Class 1 T. brucei enzyme,                                             expect finding selective inhibitors quite feasible. data presented provide                                             strong rationale pursuing research T. brucei DHODH order develop <br />                                             potent inhibitors drug leads. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                               Page 7 <br />  <br />  <br />                               Inhibitors trypanosomal Class 1A DHODH <br />                                             previous focus inhibitor studies largely directed Class 2 DHODHs. P. <br />                                             falciparum enzyme (PfDHODH) focus significant potential new <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             target development anti-malarials (Baldwin et al., 2005), human enzyme                                             targeted treatment cancer, gastric ulcers, rheumatoid arthritis (Palfey et al., 2001). <br />                                             Structural studies PfDHODH inhibitors based brequinar analogues (Boa et al., 2005), <br />                                             biphenylamides (Baldwin et al., 2005), A771726 (Heikkil&#195;&#164; et al., 2006), atovaquone (Hansen <br />                                             et al., 2004), lefluno-mide (Hurt et al., 2006) analogues bind similarly, <br />                                             attacking ubiquinone binding site formed jointly N- C-terminal domains (Figure <br />                                             2c). Unfortunately, given involvement Class 2-specific N-terminal domain, class <br />                                             inhibitors unlikely relevant Class 1 enzymes. <br />  <br />                                              inhibitors specific Class 1A enzymes known, including <br />                                             hydroxybenzoates. orotate analogs shown specifically inhibit                                             L. lactis Class 1A DHODH minimal effect L. lactis Class 1B enzyme human <br />                                             E. coli Class 2 enzymes (Palfey et al., 2001). stereochemistry protein <br />                                             residues forming orotate binding site Class 1A Class 2 enzymes nearly identical, <br />                                             redox mechanism differs classes (Fagan et al., 2007). Fagan et al. (2007)                                             attributed subtle dynamic features proteins. basis present structure, <br />                                             suggest features include differential access orotate FMN sites                                               protein (Figure 2) difference relative mobility observed <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             crystallographically residues 132&#226;&#8364;&#8220;138 pyr-binding motif (Figure 3). <br />  <br />                                             Wolfe et al. (2007) investigated structural details kinetics hydroxybenzoate <br />                                             inhibition L. lactis Class 1A DHODH. inhibitor observed crystallographically <br />                                             monomer homodimer, consistent kinetic data showing cooperativity <br />                                             monomers dimer. structural basis cooperativity                                             evident (Wolfe et al., 2007). Given high structural conservation L. lactis <br />                                             structure present T. brucei structure, plausible class inhibitors <br />                                             relevant trypanosomal homologs. shown inhibition assays <br />                                             TbDHODH hydroxybenzoate inhibitors act bacterial DHODHs                                             Class 1A DHODH eukaryotic parasite. particular, competitive <br />                                             inhibition 3,4-dihydroxybenzoate (Ki 58 &#194;&#181;M) non-competitive inhibition 3,5- <br />                                             dihydroxybenzoate (Ki 200 &#194;&#181;M). Ki values higher reported L. <br />                                             lactis remain possible starting points anti-parasitic drug design. <br />  <br />                               Applicability inhibitor design pathogens <br />                                             T. brucei representative larger class pathogenic protozoan parasites responsible NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             substantial burden human disease. evaluating importance TbDHODH possible <br />                                             drug target, drugs acting TbDHODH                                             effective related pathogens. Class 1A DHODHs primarily bacterial,                                             acquired yeasts (Saccharomyces, Kluyveromyces) apparently                                             lateral gene transfer Lactococcus (Hall et al., 2005). appearance Class 1A DHODH <br />                                             trypanosomatids similarly lateral transfer, point introduction <br />                                             clade protozoan lineages known. <br />  <br />                                             sequences T. brucei Class 1A, L. lactis Class 1B, P. falciparum Class 2 DHODH <br />                                             submitted GeneDB omni-BLAST server (Hertz-Fowler et al., 2004)                                             homologs protozoa. species contain DHODH class. <br />                                             protozoan Class 1B homologs detected. Plasmodium genomes contain Class <br />                                             2 sequences. sequences T. brucei, T.b. gambiense, T. cruzi, T. congolense, T. vivax, <br />                                             L. major, L. infantum &gt;75% sequence identity genome strain TbDHODH.  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                             Page 8 <br />  <br />  <br />                                             residues involved binding FMN orotate conserved, suggesting drug design based <br />                                             TbDHODH structure relevant pathogenic trypanosomatids. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Summary <br />                                             shown RNAi interference dihydroorotate dehydrogenase bloodstream <br />                                             form Trypanosoma brucei inhibits growth access pyrimidines environment                                             blocked. calls question general essentiality pyrimidine biosynthesis <br />                                             pathway T. brucei, distinction previous report essentiality T. cruzi.  <br />                                             shown RNAi suppression DHODH synergistic effect                                             complementary growth-blocking agent 5-FU, inhibits pyrimidine uptake.                                             demonstrates interference T. brucei DHODH potentiate activity                                             established clinical drug 5-FU bloodstream form T. brucei. <br />  <br />                                             crystal structure enzymatic properties T. brucei enzyme active site <br />                                             similar Class 1A DHODHs Class 2 DHODHs higher <br />                                             eukaryotes, including human DHODH. Encouragingly, inhibited hydroxybenzoates,                                             common Class 1A DHODHs distinction Class 2 human DHODH. <br />  <br />                                             T. brucei DHODH, extension enzymes pyrimidine biosynthetic <br />                                             pathway, remains possible target development pronged therapeutic approach <br />                                             attacking pyrimidine biosynthesis pyrimidine uptake. Furthermore, propose NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             molecular details provided present TbDHODH structure useful designing <br />                                             selective inhibitors potential lead compounds targeting protozoan dihydroorotate <br />                                             dehydrogenases. <br />  <br />                               MATERIALS METHODS <br />                               Protein expression crystallography <br />                                             gene encoding TbDHODH PCR amplified genomic DNA strain T. <br />                                             brucei TREU927 GUTat 10.1 cloned vector AVA421, based E. coli <br />                                             expression vector pET14b (Alexandrov et al., 2004). AVA421 vector contains cleavable <br />                                             N-terminal tag. protein purified using Ni-NTA column bound protein <br />                                             cleaved protease 3C overnight 4&#194;&#176;C. released protein purified gel <br />                                             filtration HiLoad Superdex 200. <br />  <br />                               Protein expression enzymatic studies <br />                                             DHODH gene amplified T. brucei brucei 427 strain genomic DNA                                             polymerase chain reaction using primers 5&#226;&#8364;&#8482;- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             CGCAAAGGGAAAAGTCATATGAGTTTGAAAGTTAAT-3&#226;&#8364;&#8482; 5&#226;&#8364;&#8482;- <br />                                             CATCAACACCCATGTATCTCGAGATCCATCGTCTTCACGC-3&#226;&#8364;&#8482;, introduced <br />                                             NdeI XhoI restriction sites. product subcloned, ligated pET22b (EMD <br />                                             Biosciences) providing C-terminus tag. resulting TbDHODH-pET22b plasmid                                             transformed BL21-DE3 E. coli cells, grown LB-Miller medium                                             OD600nm 0.8, supplemented 100 &#194;&#181;M FMN induced 200 &#194;&#181;M IPTG.                                             cell pellet collected 3 hours induction resuspended lysis buffer (50 mM sodium <br />                                             phosphate, pH 8.0, 10 mM imidazole, 5 mM 2-mercaptoethanol, 10% glycerol, 1 mg/ml <br />                                             lysozyme, 0.1 mg/ml DNAse) protease inhibitor cocktail added final <br />                                             concentration 200 &#194;&#181;M phenylmethylsulfonyl fluoride, 1 &#194;&#181;g/ml leupeptin, 2 &#194;&#181;g/ml antipain, <br />                                             10 &#194;&#181;g/ml benzamidine, 1 &#194;&#181;g/ml pepstatin 1 &#194;&#181;g/ml chymostatin. lysis mixture                                             incubated 2 hours ice constant stirring, sonicated centrifuged 20,000 &#195;&#8212; g                                             30 minutes 4&#194;&#176;C. supernatant centrifugation loaded 10 ml column                                             nickel agarose resin (Qiagen) equilibrated Wash Buffer (50 mM sodium phosphate, pH <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                              Page 9 <br />  <br />  <br />                                             8.0, 300 mM sodium chloride, 20 mM imidazole, 5 mM 2-mercaptoethanol, 10% glycerol). <br />                                             column washed volumes Wash Buffer, His6-tagged protein eluted <br />                                             Elution Buffer (50 mM sodium phosphate, pH 8.0, 300 mM sodium chloride, 300 mM <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             imidazole, 5 mM 2-mercaptoethanol, 10% glycerol). eluted protein pooled                                             concentrated 2 ml Centriprep YM-10 centrifugal filtration device (Amicon <br />                                             Millipore) applied HiPrep 26/10 Desalting Column (Amersham Biosciences) <br />                                             equilibrated 50 mM sodium phosphate, pH 8.0, 150 mM sodium chloride, 10% <br />                                             glycerol. Protein containing fractions pooled concentrated  <br />  <br />                               Crystallization <br />                                             Purified TbDHODH shipped dry ice High Throughput Crystallization Screening                                             Hauptman-Woodward Medical Research Institute (Luft et al., 2003). sample                                             rapidly thawed 30&#194;&#176;C water bath <span id='am-26' about='obo:IMR_0200265' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-27' property="oboInOwl:id" content="IMR:0200265" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasDbXref" content="KEGG:C00295" datatype="xsd:string"></span><span id='am-29' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-30' property="rdfs:label" content="Orotic acid" datatype="xsd:string"></span>orotic acid</span> (8 &#194;&#181;l 200mM orotic acid stock solution) <br />                                             added 392 &#194;&#181;l protein solution. Crystallization experiments set using                                             microbatch oil technique (Chayen et al., 1992) Robbins Scientific Tango liquid <br />                                             handling  1536 experiments contained 200 nl crystallization cocktail <br />                                             solution combined 200 nl protein solution USP grade mineral oil (Sigma cat <br />                                             #M1180) contained low birefringence 1536 microassay plate (Greiner BioOne cat# <br />                                             790801). Manual review plate images 1 week 4&#194;&#176;C identified 124 crystallization <br />                                             conditions outcomes considered suitable optimization trials. initial hits                                             optimized crystals grown sitting drop method. Crystals used data collection grew <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             drop consisting 0.4 &#194;&#181;l protein solution (14.1 mg/ml), mixed 0.4 &#194;&#181;l reservoir <br />                                             solution containing 40% PEG 1000, 0.1M Na citrate, 0.1M KBr, pH 4.0 room temperature. <br />  <br />                               X-ray crystal structure determination structural analysis <br />                                             Native crystals flash frozen directly liquid nitrogen. Data collected 1.95&#195;&#8230; <br />                                             resolution single crystal maintained 100K, X-ray wavelength corresponding                                             bromine K edge (&#206;&#187; = 0.92010&#195;&#8230;), ALS beamline 8.2.1. Data processed scaled <br />                                             using MOSFLM CCP4 program package (Collaborative Computational Project  4, <br />                                             1994) automated Wedger Scaler scripts Elves (Holton Alber, 2004). Data <br />                                             processing statistics shown Table 1. contribution anomalous dispersion                                             ordered Br atoms measured Bragg intensities insufficient solve structure using <br />                                             SAD phasing, 11 partially-occupied sites later identified refined structure. <br />                                             structure L. lactis DHODH (PDB accession code 1jue, 51% sequence identity) <br />                                             submitted Swiss-model server (Guex Peitsch, 1997; Schwede et al., 2003)                                             create hybrid homology model based structure L. lactis DHODH containing <br />                                             TbDHODH residues. model submitted Molrep (Vagin Teplyakov, 1997), <br />                                             placed copies monomeric model s.u. yielding correlation <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             coefficient 0.60. TbDHODH structure refined using Refmac5 (Murshudov et al., <br />                                             1997) reflections 21 &#195;&#8230; 1.95 &#195;&#8230; resolution, keeping 5% reflections <br />                                             Rf ree. Model building validation accomplished using Coot (Emsley Cowtan, <br />                                             2004) Molprobity (Lovell et al., 2003). Electron density region orotate binding <br />                                             site shown Fig. S5. final model consists molecules forming dimers.                                             final model monomer consists residues 1&#226;&#8364;&#8220;313, orotate, FMN molecule. <br />                                             overall model contains 11 bromide atoms, 3 glycerol molecules 638 water <br />                                             molecules. final model crystallographic structure factors deposited                                             Protein Data Bank (accession code 2b4g). <br />  <br />                               Enzyme kinetic inhibition assays <br />                                             Enzyme kinetic assays performed enzyme assay buffer (50 mM HEPES, pH 8.0, 150 <br />                                             mM NaCl, 10% glycerol) 25&#194;&#176;C. Analysis pH dependence utilized MES (pH 5.5&#226;&#8364;&#8220;6.5), <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                           Page 10 <br />  <br />  <br />                                             MOPS (6.5&#226;&#8364;&#8220;7.5), Tris (7.5&#226;&#8364;&#8220;9.0), CHES (9.0&#226;&#8364;&#8220;10.0) buffer salts place HEPES. <br />                                             Production orotate monitored 300 nm (&#206;&#181;300 = 2.65 mM&#226;&#710;&#8217;1cm&#226;&#710;&#8217;1) using fumarate, <br />                                             282 nm (&#206;&#181;282 = 6.60 mM&#226;&#710;&#8217;1cm&#226;&#710;&#8217;1) using vitamin K analogues, 296 nm (&#206;&#181;296 = <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             4.30 mM&#226;&#710;&#8217;1cm&#226;&#710;&#8217;1) using ubiquinone analogues. Reduction NAD+ monitored                                             340 nm (&#206;&#181;340 = 6.22 mM&#226;&#710;&#8217;1cm&#226;&#710;&#8217;1). Strong absorption far-UV inhibitors tested <br />                                             required use traditional electron acceptor dichlorophenolindophenol (DCIP)                                             inhibition studies reduction DCIP followed 600 nm (&#206;&#181;600 = 18.8 <br />                                             mM&#226;&#710;&#8217;1cm&#226;&#710;&#8217;1). <br />  <br />                                             DHO-dependent activity examined presence 500 &#194;&#181;M fumarate. Fumarate- <br />                                             dependent activity assayed constant DHO concentration 250 &#194;&#181;M. Data                                             analyzed using software package GraphPad Prism SigmaPlot fitted                                             Michaelis-Menten equation. <br />  <br />                                             Alternative electron acceptors (vitamin K ubiquinone analogues, NAD+) assayed                                             100 &#194;&#181;M electron acceptor (dissolved oxygen estimated ~210 &#194;&#181;M) 250 &#194;&#181;M DHO. <br />                                             Inhibitors initially examined 1 mM presence 25 &#194;&#181;M DHO 120 &#194;&#181;M DCIP, <br />                                             subsequent assays utilized 120 &#194;&#181;M DCIP various DHO inhibitor concentrations. <br />                                             experiments performed duplicate; combined data presented, kinetic <br />                                             parameters reported mean &#194;&#177; standard error fit. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Analytical ultracentrifugation <br />                                             Analytical ultracentrifugation performed Beckman XL analytical ultracentrifuge <br />                                             enzyme observed 280 nm (protein) 454 nm (FMN). Enzyme samples 5&#226;&#8364;&#8220;25 <br />                                             &#194;&#181;M centrifuged 14000 20000 rpm 4&#194;&#176;C, equilibrium sedimentation scans                                             obtained hours, equilibrium determined reached contiguous <br />                                             scans indistinguishable. Data fitted single ideal species model                                             monomer-dimer model representative result multiple experiments presented. <br />  <br />                               RNA interference <br />                                             region TbDHODH gene sequence selected RNAi using program RNAit <br />                                             (Redmond et al., 2003). Bases 413&#226;&#8364;&#8220;859 gene amplified T. brucei 927 genomic <br />                                             DNA using primers 5&#226;&#8364;&#8482;-ATACCAATGTGATGGCACAGGTCGGATATGACTTTGA-3&#226;&#8364;&#8482; <br />                                             5&#226;&#8364;&#8482;-ATACCATAGAGTTGGGTTGAGTCGAGCAAATATGATG-3&#226;&#8364;&#8482;. amplicon                                             ligated using TA cloning vector pGEM-T (Promega, cat# A3600), excised                                             enzyme BstXI. insert ligated stem-loop RNAi vector, pQuadra3,                                             described (Inoue et al., 2005). construct sequenced verify identity                                             insert, linearized NotI preparation electroporation. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             T. brucei bloodstream-form parasites expressing T7 RNA polymerase Tet repressor <br />                                             single selection marker provided G. Cross (Rockefeller University) (Wirtz et <br />                                             al., 1999). cells grown HMI-9 10% heat-inactivated fetal bovine serum                                             37&#194;&#176;C 5% <span id='am-11' about='obo:IMR_0200324' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-12' property="rdfs:label" content="CO2" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:id" content="IMR:0200324" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasDbXref" content="KEGG:C00011" datatype="xsd:string"></span>CO2</span> G418 2.5 &#194;&#181;g/ml (Hirumi Hirumi, 1989). Mid-log phase T. <br />                                             brucei (2.5 &#195;&#8212; 107) suspended 500 &#194;&#181;l cytomix (120mM KCl, 0.15 mM CaCl2, 10 <br />                                             mM K2HPO4/KH2PO4 pH 7.6, 25 mM Hepes, 2 mM Na2EDTA, 5 mM MgCl2) containing <br />                                             10 &#194;&#181;g NotI linearized pQuadra3/DHODH DNA. mixture electroporated 4mm <br />                                             gap cuvette 1.6 kV 24&#226;&#8222;&#166; resistance. Cells suspended HMI-9 medium                                             presence 2.5 &#194;&#181;g/ml phleomycin 2.5 &#194;&#181;g/ml G418. Individual clones selected                                             subsequent RNAi studies. expression dsRNA induced addition 1 &#194;&#181;g/ml <br />                                             tetracycline cultures diluted 1 &#195;&#8212; 105 cells/ml. Cultures passed 1:10&#226;&#8364;&#8220;1:20 <br />                                             dilution daily cell concentrations monitored using ATPLite Luminescence <span id='am-31' about='obo:IMR_0001351' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-32' property="rdfs:label" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:id" content="IMR:0001351" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:hasExactSynonym" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-35' property="oboInOwl:hasDbXref" content="KEGG:C00002" datatype="xsd:string"></span><span id='am-36' property="rdfs:label" content="ATP" datatype="xsd:string"></span><span id='am-37' property="rdfs:label" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-38' property="oboInOwl:hasAlternativeId" content="IMR:0100127" datatype="xsd:string"></span><span id='am-39' property="oboInOwl:hasExactSynonym" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:hasAlternativeId" content="IMR:0200394" datatype="xsd:string"></span>ATP</span> <br />                                             detection Assay (PerkinElmer, cat #6016941). <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                            Page 11 <br />  <br />  <br />                                             Separate growth experiments performed using HMI-9 medium omitted thymidine <br />                                             (normally included 16 &#194;&#181;M). pyrimidine bases medium;                                             supplemented 100 &#194;&#181;M <span id='am-79' about='obo:IMR_0200173' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-80' property="rdfs:label" content="Hypoxanthine" datatype="xsd:string"></span><span id='am-81' property="oboInOwl:hasDbXref" content="KEGG:C00262" datatype="xsd:string"></span><span id='am-82' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-83' property="oboInOwl:id" content="IMR:0200173" datatype="xsd:string"></span>hypoxanthine</span> source purines. medium NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             supplemented 10% dialyzed fetal bovine serum (Hyclone) complete pyrimidine <br />                                             depleted medium. <br />  <br />                               Northern analysis <br />                                             RNA isolated induced non-induced cultures 72 h growth using RNEasy <br />                                             kit (Qiagen). 16 &#194;&#181;g total RNA electrophoresed <span id='am-89' about='obo:IMR_0200017' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-90' property="rdfs:label" content="Formaldehyde" datatype="xsd:string"></span><span id='am-91' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-92' property="oboInOwl:hasDbXref" content="KEGG:C00067" datatype="xsd:string"></span><span id='am-93' property="oboInOwl:id" content="IMR:0200017" datatype="xsd:string"></span>formaldehyde</span> gel blotted using <br />                                             standard procedures. RNA membrane analyzed DNA probe amplified <br />                                             genomic DNA using primers 5&#226;&#8364;&#8482;-CTCGGACATGAGTTTTCCAACC-3&#226;&#8364;&#8482; 5&#226;&#8364;&#8482;- <br />                                             GGCTTCCTACTGTAATCGTG 3&#226;&#8364;&#8482; correspond bases 22&#226;&#8364;&#8220;281 DHODH open <br />                                             reading frame. blot stripped probed DNA T. brucei &#206;&#178;-tubulin gene <br />                                             standardization. <br />  <br />                               IC50 shift assay <br />                                             Sensitivity 5-FU tested trypomastigotes single marker parent line                                             single marker cells containing pQuadra3/DHODH RNAi vector uninduced cells <br />                                             cells induced 48 hours 1 &#194;&#181;g/ml tetracycline. Cells added 96 plates <br />                                             triplicate initial inoculum 2 &#195;&#8212; 104 trypomastigotes  compound stock <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             solution 5-fluorouracil (Sigma, F6627) prepared using sterile water initial <br />                                             concentration 20 mM. diluted HMI-9 concentration 120 &#194;&#181;M added <br />                                             serial dilutions final volume 200ul  Parasite growth quantified 48 hours <br />                                             addition Alamar Blue (Alamar Biosciences, DAL1100) (Raz et al., 1997). <br />  <br />                               5-FU incorporation experiment <br />                                             Incorporation 5-FU T. brucei genomic DNA measured bloodstream forms <br />                                             single marker parent cell line bloodstream forms containing pQuadra3/ <br />                                             DHODH RNAi construct. Measurements taken uninduced cultures cultures <br />                                             induced 72 hours 1 &#194;&#181;g/ml tetracycline. trypomastigotes                                             grown standard HMI-9 containing thymidine hypoxanthine, 2.5 &#194;&#181;g/ml <br />                                             neomycin. addition, cells containing pQuadra3/DHODH RNAi vector                                             grown presence 2.5 &#194;&#181;g/ml phleomycin. 72 hour induction, cells                                             transferred 96 plate pulsed 5 &#194;&#181;Ci [6-3H]-5-FU (Moravek Biochemicals, <br />                                             MT-686) 24 hours. Cell density quantification, order standardize results,                                             30 ul sample using ATPLite Luminescence ATP detection Assay                                             (PerkinElmer, cat #6016941) described  incorporation 3H-5-FU measured <br />                                             binding DNA remaining 175 &#194;&#181;l glass fiber filters cell harvester <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             (Inotech Biosystems International, , Rockville, MD), radioactivity incorporated <br />                                             parasites counted Chameleon 425-104 multilabel plate scintillation counter <br />                                             (Hidex Oy, Turku, Finland). <br />  <br />                               Antibody production Western immunoblotting <br />                                             Purified TbDHODH sent Affinity BioReagents (Golden,  antibody production <br />                                             rabbits previously described (www.bioreagents.com/index.cfm/fuseaction/content.aod). <br />                                             Antibody specificity confirmed purified TbDHODH T. brucei cells lysates <br />                                             using pre-immune post-challenge serum specific. anti-TbDHODH <br />                                             antibodies used Western blots lysates T. brucei bloodstream form cells collected <br />                                             daily time intervals induction RNAi. Standard Western blot procedures <br />                                             followed using goat-horseradish peroxidase-conjugated secondary antibody ECL <br />                                             detection (Amersham Biosciences). Relative TbDHODH protein levels determined  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                                             Page 12 <br />  <br />  <br />                                             densitometry. numerical values normalized stained bands transferred <br />                                             SDS-PAGE gel  shown). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Supplementary Material <br />                                             Refer Web version PubMed Central supplementary material. <br />  <br />  <br />                               Acknowledgments <br />                                             thank Jonathan Caruthers Meg Holmes aid data collection. reliant efforts                                             members SGPP consortium, including Eric Phizicky, Erin Quartley, Angela Lauricella, Lori Schoenfeld, <br />                                             Jennifer Ross, Frank Zucker, Thomas Earnest. thank Dr. HP Koning helpful discussions T. <br />                                             brucei transporter activities. work supported Protein Structure Initiative, award NIGMS GM64655; <br />                                             NIH award AI067921; funds Howard Hughes Medical Institute (HHMI) WGJH; National <br />                                             Institutes Health Grants AI053680 MAP. Portions work carried Advanced Light Source, <br />                                             supported Director, Office Science, Office Basic Energy Sciences, U.S. Department                                             Energy Contract  AC02-05CH11231. <br />  <br />  <br />                               REFERENCES <br />                                             Alexandrov  Vignali M, LaCount DJ, Quartley E, Vries C, Rosa DD, Babulski J, Mitchell SF, <br />                                                Schoenfeld LW, Fields S, Hol  Dumont  Phizicky EM, Grayhack EJ. facile method                                                high-throughput expression protein pairs. Mol Cell Proteomics 2004;3:934&#226;&#8364;&#8220;938. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                15240823] <br />                                             Andersen PS, Jansen PJ, Hammer K. different dihydroorotate dehydrogenases Lactococcus lactis. <br />                                                J Bacteriol 1994;176:3975&#226;&#8364;&#8220;3982. [PubMed: 8021180] <br />                                             Annoura T, Nara T, Makiuchi T, Hashimoto T, Aoki T. origin dihydroorotate dehydrogenase <br />                                                genes kinetoplastids, special reference biological significance adaptation                                                anaerobic, parasitic conditions. J Mol Evol 2005;60:113&#226;&#8364;&#8220;127. [PubMed: 15696374] <br />                                             Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA. High-throughput <br />                                                screening potent selective inhibitors Plasmodium falciparum dihy-droorotate <br />                                                dehydrogenase. J Biol Chem 2005;280:21847&#226;&#8364;&#8220;21853. [PubMed: 15795226] <br />                                             Beitz E. TEXshade: shading labeling multiple sequence alignments using LATEX2 epsilon. <br />                                                Bioinformatics 2000;16:135&#226;&#8364;&#8220;139. [PubMed: 10842735] <br />                                             Berriman M. Data mining parasite genomes. Parasitology 2004;(128 Suppl):S23&#226;&#8364;&#8220;S31. [PubMed: <br />                                                16454895] <br />                                             Boa  Canavan SP, Hirst PR, Ramsey C, Stead AMW, McConkey GA. Synthesis brequinar analogue <br />                                                inhibitors malaria parasite dihydroorotate dehydrogenase. Bioorg Med Chem 2005;13:1945&#226;&#8364;&#8220;1967. <br />                                                [PubMed: 15727850] <br />                                             Chaudhary K, Roos DS. Protozoan genomics drug discovery. Nat Biotechnol 2005;23:1089&#226;&#8364;&#8220;1091. <br />                                                [PubMed: 16151400] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Chayen NE, Stewart PDS, Blow DM. Microbatch crystallization oil &#226;&#8364;&#8220; new technique allowing <br />                                                small-volume crystallization trials. Journal Crystal Growth 1992;122:176&#226;&#8364;&#8220;180. <br />                                             Collaborative Computational Project  4. ccp4 suite: programs protein crystallography. Acta <br />                                                  Cryst 1994;D50:760&#226;&#8364;&#8220;763. <br />                                             Bono JS, Twelves CJ. oral fluorinated pyrimidines. Invest New Drugs 2001;19(1):41&#226;&#8364;&#8220;59. <br />                                                  [PubMed: 11291832] <br />                                             Koning HP, Jarvis SM. highly selective, high-affinity transporter uracil Trypanosoma brucei <br />                                                  brucei: evidence proton-dependent transport. Biochem Cell Biol 1998;76:853&#226;&#8364;&#8220;858. [PubMed: <br />                                                  10353720] <br />                                             Emsley P, Cowtan K. Coot: model-building tools molecular graphics. Acta Cryst 2004;D60:2126&#226;&#8364;&#8220; <br />                                                  2132. <br />                                             Fagan R, Jensen K, Bjornberg O, Palfey B. Mechanism flavin reduction class 1a dihydroorotate <br />                                                  dehydrogenase lactococcus lactis. Biochemistry 2007;46(13):4028&#226;&#8364;&#8220;4036. [PubMed: <br />                                                  17341096] <br />  <br />  <br />  <br />                                                   Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                                     Page 13 <br />  <br />  <br />                                             Feliciano PR, Cordeiro  Costa-Filho AJ, Nonato MC. Cloning, expression, purification,                                                 characterization Leishmania major dihydroorotate dehydrogenase. Protein Expr Purif 2006;48(1): <br />                                                 98&#226;&#8364;&#8220;103. [PubMed: 16600626] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Guda C, Lu S, Scheeff ED, Bourne PE, Shindyalov  CE-MC: multiple protein structure alignment <br />                                                 server. Nucleic Acids Res 2004;32:W100&#226;&#8364;&#8220;W103. [PubMed: 15215359] <br />                                             Gudin S, Quashie NB, Candlish D, Al-Salabi MI, Jarvis SM, Ranford-Cartwright LC, Koning HP. <br />                                                 Trypanosoma brucei: survey pyrimidine transport activities. Exp Parasitol 2006;114:118&#226;&#8364;&#8220;125. <br />                                                 [PubMed: 16620810] <br />                                             Guex N, Peitsch MC. SWISS-MODEL Swiss-PdbViewer: environment comparative <br />                                                 protein modeling. Electrophoresis 1997;18:2714&#226;&#8364;&#8220;2723. [PubMed: 9504803] <br />                                             Hall C, Brachat S, Dietrich FS. Contribution horizontal gene transfer evolution Saccharomyces <br />                                                 cerevisiae. Eukaryot Cell 2005;4(6):1102&#226;&#8364;&#8220;1115. [PubMed: 15947202] <br />                                             Hansen M, Nours JL, Johansson E, Antal T, Ullrich  L&#195;&#182;ffler M, Larsen S. Inhibitor binding class <br />                                                 2 dihydroorotate dehydrogenase causes variations membrane-associated N-terminal domain. <br />                                                 Protein Sci 2004;13:1031&#226;&#8364;&#8220;1042. [PubMed: 15044733] <br />                                             Heikkil&#195;&#164; T, Thirumalairajan S, Davies M, Parsons MR, McConkey AG, Fishwick CWG, Johnson AP. <br />                                                 novo designed inhibitors Plasmodium falciparum dihydroorotate dehydrogenase. <br />                                                 Bioorg Med Chem Lett 2006;16:88&#226;&#8364;&#8220;92. [PubMed: 16236496] <br />                                             Hertz-Fowler C, Peacock CS, Wood V, Aslett M, Kerhornou  Mooney P, Tivey  Berriman M, Hall <br />                                                 N, Rutherford K, Parkhill J, Ivens AC, Rajandream M  Barrell B. GeneDB: resource                                                 prokaryotic eukaryotic organisms. Nucleic Acids Res 2004;32:D339&#226;&#8364;&#8220;D343. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 14681429] <br />                                             Hirumi H, Hirumi K. Continuous cultivation Trypanosoma brucei blood stream forms medium <br />                                                 containing low concentration serum protein feeder cell layers. J Parasitol 1989;75:985&#226;&#8364;&#8220; <br />                                                 989. [PubMed: 2614608] <br />                                             Holton J, Alber T. Automated protein crystal structure determination using ELVES. Proc Natl Acad Sci <br />                                                 U S 2004;101:1537&#226;&#8364;&#8220;1542. [PubMed: 14752198] <br />                                             Hurt  Widom J, Clardy J. Structure Plasmodium falciparum dihydroorotate dehydrogenase                                                 bound inhibitor. Acta Crystallogr D Biol Crystallogr 2006;62:312&#226;&#8364;&#8220;323. [PubMed: 16510978] <br />                                             Inaoka DK, Takashima E, Osanai  Shimizu H, Nara T, Aoki T, Harada S, Kita K. Expression, <br />                                                 purification crystallization Trypanosoma cruzi dihydroorotate dehydrogenase complexed                                                 orotate. Acta Crystallograph Sect F Struct Biol Cryst Commun 2005;61:875&#226;&#8364;&#8220;878. <br />                                             Inoue M, Nakamura Y, Yasuda K, Yasaka N, Hara T, Schnaufer  Stuart K, Fukuma T. 14-3-3 <br />                                                 proteins Trypanosoma brucei function motility, cytokinesis, cell cycle. J Biol Chem <br />                                                 2005;280(14):14085&#226;&#8364;&#8220;14096. [PubMed: 15653691] <br />                                             Karibian D. Dihydroorotate dehydrogenase (Escherichia coli). Methods Enzymol 1978;51:58&#226;&#8364;&#8220;63. <br />                                                 [PubMed: 211391] <br />                                             Knecht W, Bergjohann U, Gonski S, Kirschbaum B, L&#195;&#182;ffler M. Functional expression fragment                                                 human dihydroorotate dehydrogenase means baculovirus expression vector                                                  kinetic investigation purified recombinant enzyme. Eur J Biochem 1996;240:292&#226;&#8364;&#8220;301. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 [PubMed: 8925840] <br />                                             Laskowski RA, Chistyakov VV, Thornton JM. PDBsum  new summaries analyses known <br />                                                 3D structures proteins nucleic acids. Nucleic Acids Res 2005;33:D266&#226;&#8364;&#8220;D268. [PubMed: <br />                                                 15608193] <br />                                             Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J. Structures human dihydroorotate <br />                                                 dehydrogenase complex antiproliferative agents. Structure 2000;8:25&#226;&#8364;&#8220;33. [PubMed: <br />                                                 10673429] <br />                                             Lovell SC, Davis IW, Arendall WB, Bakker PIW, Word JM, Prisant MG, Richardson JS, Richardson <br />                                                 DC. Structure validation Calpha geometry: phi,psi Cbeta deviation. Proteins 2003;50:437&#226;&#8364;&#8220; <br />                                                 450. [PubMed: 12557186] <br />                                             Luft JR, Collins RJ, Fehrman NA, Lauricella  Veatch CK, DeTitta GT. deliberate approach                                                 screening initial crystallization conditions biological macromolecules. J Struct Biol <br />                                                 2003;142:170&#226;&#8364;&#8220;179. [PubMed: 12718929] <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                                 Page 14 <br />  <br />  <br />                                             Marcinkeviciene J, Jiang W, Locke G, Kopcho LM, Rogers MJ, Copeland RA. second dihydroorotate <br />                                                 dehydrogenase (Type  human pathogen Enterococcus faecalis: expression, purification,                                                 steady-state kinetic mechanism. Arch Biochem Biophys 2000;377(1):178&#226;&#8364;&#8220;186. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 10775458] <br />                                             McRobert L, McConkey GA. RNA interference (RNAi) inhibits growth Plasmodium falciparum. Mol <br />                                                 Biochem Parasitol 2002;119(2):273&#226;&#8364;&#8220;278. [PubMed: 11814579] <br />                                             Murshudov GN, Vagin AA, Dodson EJ. Refinement macromolecular structures maximum- <br />                                                 likelihood method. Acta Cryst 1997;D53:240&#226;&#8364;&#8220;255. <br />                                             Nara T, Hshimoto T, Aoki T. Evolutionary implications mosaic pyrimidine-biosynthetic pathway <br />                                                 eukaryotes. Gene 2000;257:209&#226;&#8364;&#8220;222. [PubMed: 11080587] <br />                                             Nielsen FS, Andersen PS, Jensen KF. B form dihydroorotate dehydrogenase Lactococcus <br />                                                 lactis consists different subunits, encoded pyrDb pyrK genes, contains FMN, <br />                                                 FAD, [FeS] redox centers. J Biol Chem 1996;271:29359&#226;&#8364;&#8220;29365. [PubMed: 8910599] <br />                                             Nielsen FS, Rowland P, Larsen S, Jensen KF. Purification characterization dihydroorotate <br />                                                 dehydrogenase Lactococcus lactis, crystallization preliminary X-ray diffraction studies <br />                                                 enzyme. Protein Sci 1996;5:852&#226;&#8364;&#8220;856. [PubMed: 8732756] <br />                                             N&#195;&#184;rager S, Arent S, Bj&#195;&#182;rnberg O, Ottosen M, Leggio LL, Jensen KF, Larsen S. Lactococcus lactis <br />                                                 dihydroorotate dehydrogenase mutants reveal important facets enzymatic function. J Biol <br />                                                 Chem 2003;278:28812&#226;&#8364;&#8220;28822. [PubMed: 12732650] <br />                                             Palfey BA, Bj&#195;&#182;rnberg O, Jensen KF. Specific inhibition family 1A dihydroorotate dehydrogenase <br />                                                 benzoate pyrimidine analogues. J Med Chem 2001;44:2861&#226;&#8364;&#8220;2864. [PubMed: 11520193] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Papageorgiou IG, Yakob L, Salabi MIA, Diallinas G, Soteriadou KP, Koning HPD. Identification                                                 pyrimidine nucleobase transporter Leishmania: similarities Trypanosoma brucei U1 <br />                                                 transporter antileishmanial activity uracil analogues. Parasitology 2005;130:275&#226;&#8364;&#8220;283. <br />                                                 [PubMed: 15796010] <br />                                             Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. Alamar Blue assay determine drug <br />                                                 sensitivity African trypanosomes (T.b. rhodesiense T.b. gambiense) vitro. Acta Trop <br />                                                 1997;68(2):139&#226;&#8364;&#8220;147. [PubMed: 9386789] <br />                                             Redmond S, Vadivelu J, Field MC. RNAit: automated web-based tool selection RNAi targets <br />                                                 Trypanosoma brucei. Mol Biochem Parasitol 2003;128:115&#226;&#8364;&#8220;118. [PubMed: 12706807] <br />                                             Rowland P, N&#195;&#184;rager S, Jensen KF, Larsen S. Structure dihydroorotate dehydrogenase B: electron <br />                                                 transfer flavin groups bridged <span id='am-84' about='obo:IMR_0200435' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-85' property="rdfs:label" content="Iron" datatype="xsd:string"></span><span id='am-86' property="oboInOwl:hasDbXref" content="KEGG:C00023" datatype="xsd:string"></span><span id='am-87' property="oboInOwl:id" content="IMR:0200435" datatype="xsd:string"></span><span id='am-88' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>iron</span>-sulphur cluster. Structure 2000;8:1227&#226;&#8364;&#8220;1238. <br />                                                 [PubMed: 11188687] <br />                                             Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: automated protein homology-modeling <br />                                                 server. Nucleic Acids Res 2003;31:3381&#226;&#8364;&#8220;3385. [PubMed: 12824332] <br />                                             Takashima E, Inaoka DK, Osanai  Nara T, Odaka M, Aoki T, Inaka K, Harada S, Kita K. <br />                                                 Characterization dihydroorotate dehydrogenase soluble fumarate reductase                                                 Trypanosoma cruzi. Mol Biochem Parasitol 2002;122(2):189&#226;&#8364;&#8220;200. [PubMed: 12106873] <br />                                             Vagin  Teplyakov  Molrep: automated program molecular replacement. J. Appl. Cryst <br />                                                 1997;30:1022&#226;&#8364;&#8220;1025. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Wang CC. Validating targets antiparasite chemotherapy. Parasitology 1997;114:S31&#226;&#8364;&#8220;S44. Suppl <br />                                                 (NIL). [PubMed: 9309767] <br />                                             Wirtz E, Leal S, Ochatt C, Cross GA. tightly regulated inducible expression conditional <br />                                                 gene knock-outs dominant-negative genetics Trypanosoma brucei. Mol Biochem Parasitol <br />                                                 1999;99:89&#226;&#8364;&#8220;101. [PubMed: 10215027] <br />                                             Wolfe  Thymark M, Gattis S, Fagan R, Hu Y-c, Johansson E, Arent S, Larsen S, Palfey B. Interaction <br />                                                 benzoate pyrimidine analogues class 1a dihydroorotate dehydrogenase lactococcus <br />                                                 lactis. Biochemistry 2007;46(19):5741&#226;&#8364;&#8220;5753. [PubMed: 17444658] <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                          Page 15 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 1. <br />                                             Oxidation dihydroorotate orotate. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                        Page 16 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 2. <br />                                             Comparison T. brucei human DHODH. TbDHODH homodimeric, typical Class <br />                                             1A homologues. human enzyme monomeric, characteristic Class 2 homologues. <br />                                               TbDHODH monomer showing Class 1A motifs: Motif 1 (residues 195&#226;&#8364;&#8220;203, blue), Motif <br />                                             2 (residues 64&#226;&#8364;&#8220;76, green), Motif 3 (residues 214&#226;&#8364;&#8220;223, orange), Pyr-binding motif (residues <br />                                             126&#226;&#8364;&#8220;143, red). orotate FMN cofactors shown brown yellow, respectively. <br />                                             (b) Surface representation TbDHODH, showing orotate FMN sites relatively <br />                                             solvent accessible loop 132&#226;&#8364;&#8220;138 &#226;&#8364;&#732;closed&#226;&#8364;&#8482; conformation. (c) Surface <br />                                             representation entire human DHODH monomer including ordered residues (30&#226;&#8364;&#8220; <br />                                             69) N-terminal domain (brown). Class 2 homologues N-terminal domain <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                             Page 17 <br />  <br />  <br />                                             restricts solvent access orotate FMN binding sites direction. depression <br />                                             visible center surface binding site Class 2 DHODH redox partner <br />                                             ubiquinone, Class 2 specific inhibitors brequinar. (d) Surface representation <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             human DHODH N-terminal residues removed purpose comparison                                             trypanosomal enzyme. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                          Page 18 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 3. <br />                                             structure-based sequence alignment Class 1A T. brucei (current structure), Class <br />                                             1B L. lactis (PDB accession code 1ep1), Class 2 human DHODH (PDB accession code <br />                                             1d3g). active site Cys131 colored yellow. Asn residues important catalysis                                             conserved classes DHODH colored cyan. Class 1A motifs                                             aid classification DHODHs labeled discussed Fig. S2. Residue <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             numbering secondary structure elements correspond T. brucei DHODH.                                             alignment generated using CEMC Multiple Protein Structure Alignment Server <br />                                             (http://bioinformatics.albany.edu/~cemc/) (Guda et al., 2004) colored using TEXshade <br />                                             (Beitz, 2000). human sequence shown begins residue 69, omitting N-terminal <br />                                             domain present Class 1 homologues. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                              Page 19 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 4. <br />                                             Knockdown DHODH mRNA expression (Panel  DHODH protein expression (Panel <br />                                             B) induction RNAi tetracycline.  -  Northern blot T. brucei cells collected <br />                                             72 h post-tetracycline induction RNAi (TCN+) demonstrates 95% knockdown DHODH <br />                                             mRNA compared cells containing construct RNAi uninduced (TCN-).  - <br />                                              &#206;&#178;-tubulin mRNA expression levels near-equivalent RNA loading. (B) Western <br />                                             blot performed cell lysates collected day 0 (pre-induction) 7 days post- <br />                                             induction. blot probed anti-T. brucei DHODH antibody. upper band <br />                                             represents binding unidentified protein affected RNAi expression. NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             predicted DHODH protein labelled nearly absent day induction RNAi. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                           Page 20 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 5. <br />                                             Gene knockdown T. brucei DHODH using RNA interference. Cumulative cell densities                                             shown log-scale product cell number total dilution.  . Cell growth <br />                                             monitored T. brucei undergoing RNAi DHODH (TCN+) compared cells <br />                                             RNAi induction (TCN&#226;&#710;&#8217;). cells grown standard media bloodstream- <br />                                             form T. brucei. growth rate compared &quot;single marker&quot; (SM) strain T. <br />                                             brucei transfected RNAi expression vector (semi-logarithmic plot). (B). <br />                                             experiment Panel repeated using pyrimidine-depleted medium. <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                           Page 21 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 6. <br />                                             Effects different concentrations 5-FU T. brucei cells. RNAi induced                                             tetracycline 48 h, cells incubated serial dilutions 5-FU 48 h <br />                                             quantified Alamar Blue. Labeling Figure 5. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                        Page 22 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 7. <br />                                             Incorporation (3H)5-FU T. brucei cells. RNAi induced tetracycline 72 h, <br />                                             cells exposed (3H)5-FU additional 24 h harvesting quantifying <br />                                             tritium uptake DNA. Labeling Figure 5. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                    Page 23 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 8. <br />                                             Terminal electron acceptor preference TbDHODH. Activity examined presence <br />                                             250 &#194;&#181;M DHO 100 &#194;&#181;M electron acceptor ~210 &#194;&#181;M molecular oxygen. kcatapp                                             apparent kcat obtained fixed concentration DHO (0.25 mM) oxidant. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                        Page 24 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 9. <br />                                             Saturation kinetics T. brucei DHODH DHO fumarate. DHO-dependent activity <br />                                             assayed presence 500 &#194;&#181;M fumarate fumarate-dependent activity assayed <br />                                             presence 250 &#194;&#181;M DHO pH 8. Vmax 8.5 s&#226;&#710;&#8217;1, Km DHO 14 &#194;&#181;M, Km                                             fumarate 80 &#194;&#181;M. kcatapp apparent kcat obtained fixed concentration                                             substrate varied. Inset: pH-dependent T. brucei DHODH activity. Activity <br />                                             determined presence 125 &#194;&#181;M DHO 500 &#194;&#181;M fumarate. Activity peaks pH <br />                                             7.8 curve indicates ionizable groups pKa values 6.3 9.2. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                    Page 25 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 10. <br />                                             Ping-pong kinetics T. brucei DHODH. Double-reciprocal plot DHO-dependent activity <br />                                             presence varying concentrations fumarate 5 nM T. brucei DHODH produce <br />                                             parallel lines indicative ping-pong enzyme mechanism. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  Mol Microbiol. Author manuscript; available PMC 2010 27. <br />                             Arakaki et al.                                                                                      Page 26 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Figure 11. <br />                                             Inhibition TbDHODH 3,4- 3,5-dihydroxybenzoate. Activity determined varying <br />                                             concentrations DHO inhibitor 5 nM T. brucei DHODH. Double reciprocal plots <br />                                             characteristic competitive inhibition indicated concentrations 3,4 <br />                                             dihydroxybenzoate   non-competitive inhibition 3,5 dihydroxybenzoate (b). <br />  <br />  <br />  <br />  <br />                           <br /> </body></html>